Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15518279 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDR | |
| SCHEMBL2214672 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDR | |
| SCHEMBL15280012 | 0.93 | PTGDR2 (0.87) | PTGDR2 | |
| SCHEMBL15519218 | 0.93 | PTGDR2 (0.87) | PTGDR2 | |
| SCHEMBL2214398 | 0.93 | PTGDR2 (0.86) | PTGDR2PTGDR | |
| Acetic Acid SCHEMBL15280588 | 0.91 | PTGDR2 (0.84) | PTGDR2 | |
| SCHEMBL2219309 | 0.86 | PTGDR2 (0.76) | PTGDR2PTGDR | |
| SCHEMBL2217038 | 0.86 | PTGDR2 (0.76) | PTGDR2PTGDR | |
| SCHEMBL2213260 | 0.86 | PTGDR2 (0.75) | PTGDR2 | |
| SCHEMBL2189148 | 0.86 | PTGDR2 (1.00) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344497-B1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2014-03-05 | — | — | EP | claimed |
| US-8546422-B2 | Azaindole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2013-10-01 | — | — | US | claimed |
| US-20110178115-A1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-21 | — | — | US | claimed |
| EP-2344497-B1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2014-03-05 | — | — | EP | disclosed |
| EP-2344497-B1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2014-03-05 | — | — | EP | disclosed |
| US-8546422-B2 | Azaindole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2013-10-01 | — | — | US | disclosed |
| US-8546422-B2 | Azaindole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2013-10-01 | — | — | US | disclosed |
| US-8546422-B2 | Azaindole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2013-10-01 | — | — | US | disclosed |
| US-20110178115-A1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20110178115-A1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20110178115-A1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178115-A1 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | PTGDR2 2/4885PTGDR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.